ANKRD1 and medulloblastoma: Finally, we correlated their expression with patient outcome finding that altered VCAM1, TP63, ANKRD1, THBS1, and PTHLH levels correlated with lower patient survival in Group 4 medulloblastoma samples (Figure 7E,F).